Trisdecanoin

For research use only. Not for therapeutic Use.

  • CAT Number: R027349
  • CAS Number: 621-71-6
  • Molecular Formula: C33H62O6
  • Molecular Weight: 554.84
  • Purity: ≥95%
Inquiry Now

Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics[1][2][3].
Trisdecanoin (Intravenous injection (i.v.); 1h, 4h) can promote the metabolism of long chain fatty acids (LCFA) in the heart muscle of Atgl KO mice in lipotriglyceride lipase (Atgl) gene knockout (KO) mice. Effect of reducing lipid accumulation in the heart of AtglKO mice and improving left ventricular function of AtglKO mice[2].
Trisdecanoin (1145 mg/kg/day; Oral gavage (p.o.); two weeks) can prevent and inhibit the development of abdominal aortic aneurysms and alleviate the apoptosis and dysfunction of early smooth muscle cells (SMCs) in Male Sprague-Dawley rat models[3].


Catalog Number R027349
CAS Number 621-71-6
Synonyms

2,3-di(decanoyloxy)propyl decanoate

Molecular Formula C33H62O6
Purity ≥95%
InChI InChI=1S/C33H62O6/c1-4-7-10-13-16-19-22-25-31(34)37-28-30(39-33(36)27-24-21-18-15-12-9-6-3)29-38-32(35)26-23-20-17-14-11-8-5-2/h30H,4-29H2,1-3H3
InChIKey LADGBHLMCUINGV-UHFFFAOYSA-N
SMILES CCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC
Reference

[1]. Tricaprin (Code C153424)

[2]. Suzuki A, et al. Tricaprin Rescues Myocardial Abnormality in a Mouse Model of Triglyceride Deposit Cardiomyovasculopathy. J Oleo Sci. 2018;67(8):983-989.
 [Content Brief]

[3]. Kugo H, et al. Tricaprin can prevent the development of AAA by attenuating aortic degeneration. Biomed Pharmacother. 2023;160:114299.
 [Content Brief]

Request a Quote